Zynerba Pharmaceuticals I... (ZYNE)
NASDAQ: ZYNE
· Real-Time Price · USD
1.30
0.03 (2.36%)
At close: Oct 10, 2023, 10:00 PM
Zynerba Pharmaceuticals Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -37.58M | -36.66M | -35.04M | -35.83M | -37.74M | -37.84M | -37.31M | -38.11M | -36.58M | -46.96M |
Depreciation & Amortization | 221.89K | 210.23K | 219.28K | 227.81K | 238.52K | 246.38K | 247.14K | 245.03K | 240.92K | 227.27K |
Stock-Based Compensation | 3.65M | 3.99M | 4.33M | 4.35M | 4.88M | 5.71M | 5.81M | 6.01M | 5.71M | 5.12M |
Other Working Capital | 1.21M | 747.37K | 7.39M | 7.17M | 7.19M | 7.04M | -1.48M | 4.55K | -2.45M | 4.47M |
Other Non-Cash Items | 7.46M | 7.46M | 7.46M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Deferred Income Tax | -7.46M | -7.46M | -7.46M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | 2.06M | 1.35M | 7.46M | 6.08M | 7.06M | 6.92M | -2.21M | -756.4K | -4.6M | 3.01M |
Operating Cash Flow | -31.64M | -31.11M | -23.03M | -25.18M | -25.56M | -24.96M | -33.46M | -32.61M | -35.23M | -38.61M |
Capital Expenditures | -200.45K | -192.05K | -154.1K | -146.71K | -51.61K | -99.18K | -47.57K | -109.66K | -132.05K | -307.11K |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | -200.45K | -192.05K | -154.1K | -146.71K | -51.61K | -99.18K | -47.57K | -109.66K | -132.05K | -307.11K |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 5.32M | 6M | 6.01M | 5.61M | 2.32M | 1.63M | 42.16M | 44.05M | 44.14M | 71.41M |
Financial Cash Flow | 5.32M | 6M | 6.01M | 5.61M | 2.32M | 1.63M | 42.16M | 44.05M | 44.14M | 71.41M |
Net Cash Flow | -26.52M | -25.3M | -17.17M | -19.71M | -23.29M | -23.43M | 8.65M | 11.33M | 8.77M | 32.49M |
Free Cash Flow | -31.84M | -31.3M | -23.18M | -25.32M | -25.62M | -25.06M | -33.51M | -32.72M | -35.36M | -38.92M |